|
FDA Advisers Echo Staff Concerns About Efficacy of Pfizer’s Neuro Drug Vyndaqel
A panel of FDA advisers believes Pfizer’s neurodegenerative disorder drug Vyndaqel lacks the confirmatory evidence needed to support approval.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives